New research helps explain why a subset of patients with relapsing/remitting multiple sclerosis (MS) experience long-term ...

Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly reduce brain volume loss compared with placebo. Indirect treatment comparisons reveal varying impacts of disease ...

Background: Interleukin-17A (IL-17A) is the founding member of a novel family of inflammatory cytokines that plays a critical role in the pathogenesis of many autoimmune diseases, including ...

Urges Vanda Shareholders to Express Their Views on the Proposal to the Independent Directors of the Vanda Board of Directors Boston, MA & Cambridge, U.K. – October 14, 2024 – Cycle Pharmaceuticals Ltd ...

Fingolimod (FTY720), an immunomodulator that acts on sphingosine-1-phosphate receptors, is the first oral disease-modifying agent to be approved by the US FDA for the treatment of relapsing forms ...

We would like to use cookies to collect information about how you use ons.gov.uk. We use this information to make the website work as well as possible and improve our services.